KARINA GONZÁLEZ GARCÍA

Ms. KARINA GONZÁLEZ GARCÍA

Universidad Autónoma Benito Juárez de Oaxaca, Oaxaca, Mexico
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
IRItayetzi Reyes-Avendaño
Itayetzi Reyes-Avendaño
EREdilburga Reyes-Jiménez
Edilburga Reyes-Jiménez
KGKARINA GONZÁLEZ GARCÍA
KARINA GONZÁLEZ GARCÍA
DPDulce Pérez-Figueroa
Dulce Pérez-Figueroa
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos
Verónica Rocío Vásquez-GarzónVerónica Rocío Vásquez-Garzón
Verónica Rocío Vásquez-Garzón
Hepatocellular carcinoma (HCC) is a health problem worldwide due to its high mortality rate, and the tumor microenvironment (TME) plays a key role in the HCC progression. The current ineffective therapies to fight the disease still warrant the development of preventive strategies. Quercetin has been shown to have different antitumor activities; however, its effect on TME components in preneoplastic lesions has not been fully investigated yet. Here, we aimed to evaluate the effect of quercetin (10 mg/kg) on TME components during the early stages of HCC progression induced in the rat. Histopathological and immunohistochemical analyses showed that quercetin decreases the size of preneoplastic lesions, glycogen and collagen accumulation, the expression of cancer stem cells and myofibroblasts markers, and that of the transporter ATP binding cassette subfamily C member 3 (ABCC3), a marker of HCC progression and multi-drug resistance. Our results strongly suggest that quercetin has the capability to reduce key components of TME, as well as the expression of ABCC3. Thus, quercetin can be an alternative treatment for inhibiting the growth of early HCC tumors.

11 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
ARAlma Aurora Ramírez-Hernández
Alma Aurora Ramírez-Hernández
Juan Manuel Velázquez-EnríquezJuan Manuel Velázquez-Enríquez
Juan Manuel Velázquez-Enríquez
JSJovito Santos
Jovito Santos
ALArmando López-Martínez
Armando López-Martínez
EREdilburga Reyes-Jiménez
Edilburga Reyes-Jiménez
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos
Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease of unknown etiology. Different types of cells are involved in fibrogenesis, which is persistently physical and molecular stimulation, either directly or by interacting with bioactive molecules and extracellular vesicles (EVs). Current evidence suggests that EVs play an essential role in IPF development. EVs are released by a variety of cells, including fibroblasts, epithelial cells, and alveolar macrophages. In addition, EVs can transport bioactive molecules, such as lipids, proteins, and nucleic acids, which play a pivotal role in cellular communication. Several proposed mechanisms show that an acceptor cell can capture, absorb, or interact with EVs through direct fusion with the plasma membrane, ligand–receptor interaction, and endocytotic process, modifying the target cell. During fibrogenesis, the release of EVs is deregulated, increases the EVs amount, and the cargo content is modified. This alteration is closely associated with the maintenance of the fibrotic microenvironment. This review summarizes the current data on the participation of EVs secreted by the cells playing a critical role in IPF pathogenesis.

25 March 2022 in Cells
Verified
Journal Article
Open access
PDF file
JSJovito Santos
Jovito Santos
Juan Manuel Velázquez-EnríquezJuan Manuel Velázquez-Enríquez
Juan Manuel Velázquez-Enríquez
RCRosendo García Carrillo
Rosendo García Carrillo
CRCésar Rodríguez-Beas
César Rodríguez-Beas
ARAlma Ramírez-Hernández
Alma Ramírez-Hernández
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease. Lesions in the lung epithelium cause alterations in the microenvironment that promote fibroblast accumulation. Extracellular vesicles (EVs) transport proteins, lipids, and nucleic acids, such as microRNAs (miRNAs). The aim of this study was to characterize the differentially expressed miRNAs in the cargo of EVs obtained from the LL97 and LL29 fibroblast cell lines isolated from IPF lungs versus those derived from the CCD19 fibroblast cell line isolated from a healthy donors. We characterized EVs by ultracentrifugation, Western blotting, and dynamic light scattering. We identified miRNAs by small RNA-seq, a total of 1144 miRNAs, of which 1027 were known miRNAs; interestingly, 117 miRNAs were novel. Differential expression analysis showed that 77 miRNAs were upregulated and 68 were downregulated. In addition, pathway enrichment analyses from the Gene Ontology and Kyoto Encyclopedia of Genomes identified several miRNA target genes in the categories, cell proliferation, regulation of apoptosis, pathways in cancer, and proteoglycans in cancer. Our data reveal that miRNAs contained in EVs cargo could be helpful as biomarkers for fibrogenesis, diagnosis, and therapeutic intervention of IPF.

Verified
Journal Article
Open access
PDF file
KGKARINA GONZÁLEZ GARCÍA
KARINA GONZÁLEZ GARCÍA
ALArmando López-Martínez
Armando López-Martínez
Juan Manuel Velázquez-EnríquezJuan Manuel Velázquez-Enríquez
Juan Manuel Velázquez-Enríquez
ZZZertuche-Martínez Zertuche-Martínez
Zertuche-Martínez Zertuche-Martínez
GTGABRIELA CARRASCO TORRES
GABRIELA CARRASCO TORRES
Verónica Rocío Vásquez-GarzónVerónica Rocío Vásquez-Garzón
Verónica Rocío Vásquez-Garzón
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by parenchymal scarring, leading progressively to alveolar architecture distortion, respiratory failure, and eventually death. Currently, there is no effective treatment for IPF. Previously, 3′5-dimaleamylbenzoic acid (3′5-DMBA), a maleimide, demonstrated pro-apoptotic, anti-inflammatory, and anti-cancer properties; however, its potential therapeutic effects on IPF have not been addressed. Bleomycin (BLM) 100 U/kg was administered to CD1 mice through an osmotic minipump. After fourteen days of BLM administration, 3′5-DMBA (6 mg/kg or 10 mg/kg) and its vehicle carboxymethylcellulose (CMC) were administered intragastrically every two days until day 26. On day 28, all mice were euthanized. The 3′5-DMBA effect was assessed by histological and immunohistochemical staining, as well as by RT-qPCR. The redox status on lung tissue was evaluated by determining the glutathione content and the GSH/GSSG ratio. 3′5-DMBA treatment re-established typical lung histological features and decreased the expression of BLM-induced fibrotic markers: collagen, α-SMA, and TGF-β1. Furthermore, 3′5-DMBA significantly reduced the expression of genes involved in fibrogenesis. In addition, it decreased reduced glutathione and increased oxidized glutathione content without promoting oxidative damage to lipids, as evidenced by the decrease in the lipid peroxidation marker 4-HNE. Therefore, 3′5-DMBA may be a promising candidate for IPF treatment.

Verified
Journal Article
Open access
PDF file
Juan Manuel Velázquez-EnríquezJuan Manuel Velázquez-Enríquez
Juan Manuel Velázquez-Enríquez
ARAlma Ramírez-Hernández
Alma Ramírez-Hernández
LNLuis Manuel Sánchez Navarro
Luis Manuel Sánchez Navarro
IRItayetzi Reyes-Avendaño
Itayetzi Reyes-Avendaño
KGKARINA GONZÁLEZ GARCÍA
KARINA GONZÁLEZ GARCÍA
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, irreversible lung disorder of unknown cause. This disease is characterized by profibrotic activation of resident pulmonary fibroblasts resulting in aberrant deposition of extracellular matrix (ECM) proteins. However, although much is known about the pathophysiology of IPF, the cellular and molecular processes that occur and allow aberrant fibroblast activation remain an unmet need. To explore the differentially expressed proteins (DEPs) associated with aberrant activation of these fibroblasts, we used the IPF lung fibroblast cell lines LL97A (IPF-1) and LL29 (IPF-2), compared to the normal lung fibroblast cell line CCD19Lu (NL-1). Protein samples were quantified and identified using a label-free quantitative proteomic analysis approach by liquid chromatography-tandem mass spectrometry (LC-MS/MS). DEPs were identified after pairwise comparison, including all experimental groups. Gene Ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG), and Protein–Protein Interaction (PPI) network construction were used to interpret the proteomic data. Eighty proteins expressed exclusively in the IPF-1 and IPF-2 clusters were identified. In addition, 19 proteins were identified up-regulated in IPF-1 and 10 in IPF-2; 10 proteins were down-regulated in IPF-1 and 2 in IPF-2 when compared to the NL-1 proteome. Using the search tool for retrieval of interacting genes/proteins (STRING) software, a PPI network was constructed between the DEPs and the 80 proteins expressed exclusively in the IPF-2 and IPF-1 clusters, containing 115 nodes and 136 edges. The 10 hub proteins present in the IPP network were identified using the CytoHubba plugin of the Cytoscape software. GO and KEGG pathway analyses showed that the hub proteins were mainly related to cell adhesion, integrin binding, and hematopoietic cell lineage. Our results provide relevant information on DEPs present in IPF lung fibroblast cell lines when compared to the normal lung fibroblast cell line that could play a key role during IPF pathogenesis.

8 September 2025 in Pathophysiology
Verified
Journal Article
Open access
PDF file
Juan Manuel Velázquez-EnríquezJuan Manuel Velázquez-Enríquez
Juan Manuel Velázquez-Enríquez
JSJovito Santos
Jovito Santos
KGKARINA GONZÁLEZ GARCÍA
KARINA GONZÁLEZ GARCÍA
IRItayetzi Reyes-Avendaño
Itayetzi Reyes-Avendaño
Victor Acevedo-SánchezVictor Acevedo-Sánchez
Victor Acevedo-Sánchez
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos
Tenascin-C (TNC) is an extracellular matrix (ECM) protein with key roles in various biological processes, such as embryonic development and tissue regeneration. However, its deregulated expression can contribute to pathological responses, promoting chronic inflammation, fibrosis, or tumor progression. It belongs to the tenascin family, a class of extracellular proteins that interfere with cellular events in both physiological and pathological contexts, interacting specifically with cells and other components of the ECM. TNC has emerged as a key player in the pathogenesis of chronic respiratory diseases (CRDs), including asthma, chronic obstructive pulmonary disease (COPD), lung cancer (LC), pulmonary hypertension (PH), and idiopathic pulmonary fibrosis (IPF). The influence of TNC on cellular responses, which is mediated by precise interactions with cellular receptors and ligands, triggers complex intracellular signaling cascades associated with the inflammatory response, fibrosis, and tumorigenesis in these CRDs. This review synthesizes recent evidence highlighting the multifaceted roles and underlying mechanisms of TNC in the context of these CRDs.